281 related articles for article (PubMed ID: 27067365)
1. The effect of macrophage and angiogenesis inhibition on the drug release and absorption from an intramuscular sustained-release paliperidone palmitate suspension.
Darville N; van Heerden M; Mariën D; De Meulder M; Rossenu S; Vermeulen A; Vynckier A; De Jonghe S; Sterkens P; Annaert P; Van den Mooter G
J Control Release; 2016 May; 230():95-108. PubMed ID: 27067365
[TBL] [Abstract][Full Text] [Related]
2. Intramuscular administration of paliperidone palmitate extended-release injectable microsuspension induces a subclinical inflammatory reaction modulating the pharmacokinetics in rats.
Darville N; van Heerden M; Vynckier A; De Meulder M; Sterkens P; Annaert P; Van den Mooter G
J Pharm Sci; 2014 Jul; 103(7):2072-2087. PubMed ID: 24845884
[TBL] [Abstract][Full Text] [Related]
3. Multimodal non-linear optical imaging for the investigation of drug nano-/microcrystal-cell interactions.
Darville N; Saarinen J; Isomäki A; Khriachtchev L; Cleeren D; Sterkens P; van Heerden M; Annaert P; Peltonen L; Santos HA; Strachan CJ; Van den Mooter G
Eur J Pharm Biopharm; 2015 Oct; 96():338-48. PubMed ID: 26347923
[TBL] [Abstract][Full Text] [Related]
4. Modeling the Time Course of the Tissue Responses to Intramuscular Long-acting Paliperidone Palmitate Nano-/Microcrystals and Polystyrene Microspheres in the Rat.
Darville N; van Heerden M; Erkens T; De Jonghe S; Vynckier A; De Meulder M; Vermeulen A; Sterkens P; Annaert P; Van den Mooter G
Toxicol Pathol; 2016 Feb; 44(2):189-210. PubMed ID: 26698322
[TBL] [Abstract][Full Text] [Related]
5. Need for Bioequivalence Standards that Reflect the Clinical Importance of the Complex Pharmacokinetics of Paliperidone Palmitate Long-Acting Injectable Suspension.
Procyshyn RM; Lamoure JW; Katzman MA; Skinner PL; Sherman SE
J Pharm Pharm Sci; 2019; 22(1):548-566. PubMed ID: 31730504
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study.
Ravenstijn P; Remmerie B; Savitz A; Samtani MN; Nuamah I; Chang CT; De Meulder M; Hough D; Gopal S
J Clin Pharmacol; 2016 Mar; 56(3):330-9. PubMed ID: 26189570
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia.
Magnusson MO; Samtani MN; Plan EL; Jonsson EN; Rossenu S; Vermeulen A; Russu A
Clin Pharmacokinet; 2017 Apr; 56(4):421-433. PubMed ID: 27743205
[TBL] [Abstract][Full Text] [Related]
8. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data.
Samtani MN; Gopal S; Gassmann-Mayer C; Alphs L; Palumbo JM
CNS Drugs; 2011 Oct; 25(10):829-45. PubMed ID: 21936586
[TBL] [Abstract][Full Text] [Related]
9. Development of near zero-order release PLGA-based microspheres of a novel antipsychotic.
Zhao J; Wang L; Fan C; Yu K; Liu X; Zhao X; Wang D; Liu W; Su Z; Sun F; Li Y
Int J Pharm; 2017 Jan; 516(1-2):32-38. PubMed ID: 27825865
[TBL] [Abstract][Full Text] [Related]
10. Dosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial Data.
Magnusson MO; Samtani MN; Plan EL; Jonsson EN; Rossenu S; Vermeulen A; Russu A
CNS Drugs; 2017 Apr; 31(4):273-288. PubMed ID: 28258365
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia.
Rossenu S; Cleton A; Hough D; Crauwels H; Vandebosch A; Berwaerts J; Eerdekens M; Herben V; De Meulder M; Remmerie B; Francetic I
Clin Pharmacol Drug Dev; 2015 Jul; 4(4):270-8. PubMed ID: 27136907
[TBL] [Abstract][Full Text] [Related]
12. Model-Informed Clinical Development of 6-Monthly Injection of Paliperidone Palmitate in Patients with Schizophrenia: Dosing Strategies Guided by Population Pharmacokinetic Modeling and Simulation (Part II).
T'jollyn H; Venkatasubramanian R; Neyens M; Gopal S; Russu A; Nandy P; Perez-Ruixo JJ; Ackaert O
Eur J Drug Metab Pharmacokinet; 2024 Jul; 49(4):491-506. PubMed ID: 38769284
[TBL] [Abstract][Full Text] [Related]
13. Rats and rabbits as pharmacokinetic screening tools for long acting intramuscular depots: case study with paliperidone palmitate suspension.
Patel H; Patel P; Modi N; Patel P; Wagh Y; George A; Desai N; Srinivas NR
Xenobiotica; 2019 Apr; 49(4):415-421. PubMed ID: 29642738
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic.
Samtani MN; Vermeulen A; Stuyckens K
Clin Pharmacokinet; 2009; 48(9):585-600. PubMed ID: 19725593
[TBL] [Abstract][Full Text] [Related]
15. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
Einarson TR; Maia-Lopes S; Goswami P; Bereza BG; Van Impe K
J Med Econ; 2016 Sep; 19(9):913-21. PubMed ID: 27124697
[TBL] [Abstract][Full Text] [Related]
16. Paliperidone palmitate three-month depot formulation: a helpful innovation with practical pitfalls.
Hope JD; Keks NA
Australas Psychiatry; 2018 Apr; 26(2):206-209. PubMed ID: 29359582
[TBL] [Abstract][Full Text] [Related]
17. Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?
Patel R; Chesney E; Taylor M; Taylor D; McGuire P
Psychol Med; 2018 Jul; 48(10):1616-1623. PubMed ID: 29039277
[TBL] [Abstract][Full Text] [Related]
18. A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia.
Cleton A; Rossenu S; Crauwels H; Berwaerts J; Hough D; Gopal S; Eerdekens M; Vandebosch A; Remmerie B; De Meulder M; Rosso CM
J Clin Pharmacol; 2014 Sep; 54(9):1048-57. PubMed ID: 24676998
[TBL] [Abstract][Full Text] [Related]
19. Breakthrough symptoms after switching long-acting injectable paliperidone palmitate from the gluteal to the deltoid site of administration.
Procyshyn RM; Banasch JL; Barr AM; Honer WG
J Psychiatry Neurosci; 2016 Apr; 41(3):E56-7. PubMed ID: 27116902
[No Abstract] [Full Text] [Related]
20. Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia.
Rosenheck RA; Leslie DL; Sint KJ; Lin H; Li Y; McEvoy JP; Byerly MJ; Hamer RM; Swartz MS; Stroup TS
Psychiatr Serv; 2016 Oct; 67(10):1124-1130. PubMed ID: 27247177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
